Search clinical trials for: Head and neck squamous cell carcinoma (HNSCC)

Total 472237 results

Cofactor Genomics, Inc.

Recruiting

Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer (PREDAPT-HNSCC2)

Head and Neck Squamous Cell Carcinoma

United States
Washington University School of Medicine
Eli Lilly and Company

Recruiting

Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (Rambro2)

Recurrent Head and Neck Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | HNSCC | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell Carcinoma

United States
All India Institute of Medical Sciences, New Delhi

Unknown

Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer.

HEAD AND NECK CANCER | CARCINOMA OROPHARYNX | CARCINOMA PYRIFORM SINUS | CARCINOMA LARYNX

India
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

Head and Neck Squamous Cell Carcinoma

China
Yale University

Completed

Window Trial 5-aza in HNSCC, T-tare

Head and Neck Squamous Cell Carcinoma

United States
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

Head and Neck Squamous Cell Carcinoma

China
Immutep S.A.S.
Merck Sharp & Dohme LLC

Recruiting

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003)

HNSCC

United States, Belgium, Spain, United Kingdom, Denmark, Germany, Australia, Romania, Ukraine
Navidea Biopharmaceuticals

Terminated

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Hannover Medical School

Completed

Efficacy Study of Temsirolimus to Treat Head and Neck Cancer (TEMHEAD)

Head and Neck Squamous Cell Carcinoma

Germany
Celgene

Completed

Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Carcinoma, Squamous Cell of Head and Neck

United States
University of Chicago

Active, not recruiting

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck

United States
Eye & ENT Hospital of Fudan University

Not yet recruiting

Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery

Head and Neck Squamous Cell Carcinoma

China
Seagen Inc.

Terminated

A Safety Study of SGN-CD47M in Patients With Solid Tumors

Melanoma | Soft Tissue Sarcoma | Colorectal Cancer | Non-small Cell Lung Carcinoma | Breast Carcinoma | Head and Neck Squamous Cell Carcinoma | Gastric Carcinoma | Ovarian Carcinoma | Exocrine Pancreatic Carcinoma

United States
Rigshospitalet, Denmark

Recruiting

PET/CT Follow up for Head and Neck Squamous Cell Carcinoma (PET Follow)

Head and Neck Squamous Cell Carcinoma | PET/CT

Denmark
Shengyu Zhou

Unknown

Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma ) (HNSCC)

Head and Neck Squamous Cell Cancer

China
Millennium Pharmaceuticals, Inc.

Completed

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Metastatic Breast Cancer | Head and Neck Squamous Cell Carcinoma | Gastroesophageal Adenocarcinoma | Advanced Nonhematological Malignancies

United States
University Hospital, Antwerp
Agentschap voor Innovatie door Wetenschap en Technologie

Completed

Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) (ECLYPS)

Locally Advanced Squamous Cell Carcinoma of the Head and Neck Region

Belgium, Netherlands
Washington University School of Medicine
Novartis Pharmaceuticals

Completed

Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (HNSCC)

Squamous Cell Carcinoma of the Head and Neck

United States
Nanobiotix

Recruiting

NBTXR3 With or Without Cetuximab in LA-HNSCC

Aged | Locally Advanced Head and Neck Squamous Cell Carcinoma

France, Spain, Israel, United States, Taiwan, Finland, Japan, Belgium, Korea, Republic of, Hungary, China, Georgia, Portugal, Austria, Bulgaria, Canada, Czechia, Germany, Greece, Romania, Serbia
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital... and other collaborators

Recruiting

PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-003)

Radiotherapy | HNSCC | PD-1

China
Yonsei University

Recruiting

HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy (TRINITY)

Head and Neck Squamous Cell Carcinoma

Korea, Republic of
University Hospital Ostrava

Completed

Prognostic Immune Biomarkers in HNSCC

Head and Neck Cancer | Squamous Cell Carcinoma

Czechia
Chang Gung Memorial Hospital

Unknown

WGA in Platinum-refractory HNSCC Underwent Nivolumab

HNSCC

Taiwan
Yonsei University

Not yet recruiting

Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients (NEOS)

Head and Neck Squamous Cell Carcinoma

Korea, Republic of
Second Affiliated Hospital, School of Medicine,...

Recruiting

Real-world Analysis on the Efficacy and Safety of Neoadjuvant Therapy for Head and Neck Squamous Cell Carcinoma （neoHNSCC）

Head and Neck Squamous Cell Carcinoma

China
European Organisation for Research and Treatment...
Danish Head and Neck Cancer Group

Active, not recruiting

AF CRT +/- Nimorazole in HNSCC

Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers

Belgium, France, Poland, Australia, Germany, Netherlands, Switzerland
Groupe Oncologie Radiotherapie Tete et Cou
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC (ELAN-RT)

Head and Neck Squamous Cell Carcinoma

France, Monaco
Memorial Sloan Kettering Cancer Center

Completed

Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

United States
Hospices Civils de Lyon

Recruiting

Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx) (CTCO)

Oropharyngeal Cancer | Circulating Tumor Cell

France
Oslo University Hospital
Bristol-Myers Squibb

Recruiting

REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors (REPORT)

Head and Neck Squamous Cell Carcinoma

Norway
Aalborg University Hospital

Recruiting

Specific Methylation Profiles in HNSCC

Head and Neck Squamous Cell Carcinoma

Denmark
M.D. Anderson Cancer Center

Terminated

Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations (HNSCC)

HNSCC

United States
GlaxoSmithKline
iTeos Therapeutics

Recruiting

Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Neoplasms, Head and Neck

United States, Italy, Spain, Taiwan, Germany, Greece, Korea, Republic of, Romania, Sweden, Turkey, Canada, Argentina, Finland, Brazil, Japan, Poland, Portugal, France, Denmark, Hungary, Norway
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

Head and Neck Squamous Cell Carcinoma

China
Groupe Oncologie Radiotherapie Tete et Cou
UNICANCER

Active, not recruiting

Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (REACH)

HNSCC

France
Lyvgen Biopharma Holdings Limited

Not yet recruiting

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma

China
BeiGene

Recruiting

Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

China, Italy, Taiwan, Australia, Spain, Korea, Republic of, France, United Kingdom, Thailand, Canada, United States, Georgia, Singapore, Turkey
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Olaparib in LA-HNSCC

Squamous Cell Carcinoma of Head and Neck

United States
University of Erlangen-Nürnberg Medical School

Recruiting

Radiotherapy With Pembrolizumab in Metastatic HNSCC

Head and Neck Squamous Cell Carcinoma

Germany
Presage Biosciences
Bristol-Myers Squibb; Celgene

Terminated

Intratumoral Microdosing of Motolimod in HNSCC

HNSCC

United States
ALX Oncology Inc.
Merck Sharp & Dohme LLC

Recruiting

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States, Belgium, Spain, Australia
Tempus AI
AstraZeneca

Recruiting

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma

United States
ALX Oncology Inc.
Merck Sharp & Dohme LLC

Recruiting

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States, Korea, Republic of, United Kingdom, Spain, Belgium, Singapore, Canada, Netherlands, Australia
Regeneron Pharmaceuticals
Sanofi

Recruiting

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States
Jiang Feng

Recruiting

Neoadjuvant SBRT in Localized Advanced HNSCC

Head and Neck Squamous Carcinoma

China
Fudan University

Completed

Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Cancer

China
Groupe Oncologie Radiotherapie Tete et Cou
AIO-Studien-gGmbH; Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Completed

Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC (TPExtreme)

Head and Neck Squamous Cell Carcinoma

France, Germany, Spain
Dan Zandberg
Merck Sharp & Dohme LLC; ISA Pharmaceuticals

Recruiting

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma | HPV-Related Squamous Cell Carcinoma

United States
Ascendis Pharma Oncology Division A/S

Recruiting

TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (BelieveIT-201)

Head and Neck Neoplasms

United States, Spain, Georgia, Hungary, Germany, Italy, Taiwan
Yonsei University

Active, not recruiting

A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)

Korea, Republic of

Search clinical trials for: Head and neck squamous cell carcinoma (HNSCC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations